PDE4B and idiopathic pulmonary fibrosis: The suitability of including ECs in RCT in IPF is supported by a recent phase II trial investigating the safety and efficacy of BI1015550 (nerandomilast), an oral preferential inhibitor of the PDE4B subtype in patients with IPF [30].